COMPANY NEWS


Marksans Pharma Ltd
BSE Code 524404 ISIN Demat INE750C01026 Book Value (₹) 25.68 NSE Symbol MARKSANS Div & Yield % 0.3 Market Cap ( Cr.) 7,558.77 P/E * 63.66 EPS * 2.62 Face Value (₹) 1
* Profit to Earning Ratio
* Earning Per Share
Marksans Pharma receives USFDA approval for Esomeprazole Magnesium Delayed-Release Capsules Back
(03 Oct 2023)
Marksans Pharma has received final approval from USFood & Drugs Administration for its Abbreviated New Drug Application (ANDA) for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg (OTC).

This product is bioequivalent to the reference listed drug (RLD), Nexium 24 HR Delayed Release Capsules, 2.0mg (OTC), of AstraZeneca Pharmaceuticals LP.

Esomeprazole is used to treat certain stomach and esophagus problems "'(such as acid reflux and ulcer). It works by decreasing the amount of acid your stomach makes. It relieves symptoms such as heartburn, difficulty swallowing, and cough. This medication helps heal acid damage to the stomach and esophagus, helps prevent ulcers and is expected to helpprevent cancer of the esophagus. Esomeprazole belongs to a class of drugs known as proton pump inhibitors (PPIs).